Arnhem, Netherlands

Peter H G Wiegerinck


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Peter H G Wiegerinck

Introduction

Peter H G Wiegerinck is a notable inventor based in Arnhem, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of water-soluble analogs of paclitaxel, a well-known antitumor agent. His work has the potential to enhance the effectiveness of cancer treatments.

Latest Patents

Peter H G Wiegerinck holds a patent for "Water soluble analogs and prodrugs of paclitaxel." This invention relates to water-soluble antitumor analogs of paclitaxel, characterized by specific chemical formulas. The patent outlines the composition of these analogs, which include various pharmaceutically acceptable counterions, and emphasizes their potential as effective treatments in oncology.

Career Highlights

Peter is associated with Pharmachemie B.V., where he has been instrumental in advancing pharmaceutical innovations. His expertise in drug formulation and development has contributed to the company's reputation in the industry. With a focus on improving drug solubility and efficacy, he continues to push the boundaries of pharmaceutical science.

Collaborations

Peter has collaborated with notable colleagues, including Duncan Sperling and Lesly Braamer. Their combined efforts in research and development have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Peter H G Wiegerinck's contributions to the field of pharmaceuticals, particularly through his patent on water-soluble analogs of paclitaxel, highlight his role as an influential inventor. His work not only advances cancer treatment options but also exemplifies the importance of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…